

Louisiana Medicaid Stimulants and Related Agents

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request:

- Clinical authorization for **all** preferred and non-preferred agents for recipients younger than ~~6~~7 years of age; **OR**
- Prior authorization for non-preferred agents for recipients ~~6~~7 years of age and older.

Additional Point-of-Sale edits may apply.

These agents may have **Black Box Warnings** and/or may be subject to **Risk Evaluation and Mitigation Strategy (REMS)** under FDA safety regulations. Please refer to individual prescribing information for details.

Initial and Reauthorization Approval Criteria for ALL Stimulants and Related Agents (both preferred and non-preferred) for Children under ~~6~~7 years of Age [except armodafinil (Nuvigil®), modafinil (Provigil®) or pitolisant (Wakix®)]:

- For ~~d~~dexmethylphenidate ER Capsules (generic for Focalin XR®) - there has been a treatment failure or intolerable side effect with or contraindication to brand Focalin XR®; **AND/OR**
- ~~There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; AND~~
- ~~For Dextroamphetamine Solution (generic for ProCentra®) - there has been treatment failure or intolerable side effect with or contraindication to brand ProCentra®; AND~~
- Previous use of a preferred product - ONE of the following is required:
 - ~~For all non-preferred agents, the following conditions apply:~~
 - ~~There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; AND~~
 - The child has had *treatment failure* with at least one preferred product; **OR**
 - The child has had an *intolerable side effect* to at least one preferred product; **OR**
 - The child has *documented contraindication(s)* to the preferred products that are appropriate for the condition being treated; **OR**
 - There is *no preferred product that is appropriate* to use for the condition being treated; **AND**
- The child has a diagnosis approved for the medication requested (see POS Edits); **AND**
- **ONE** of the following (due to this diagnosis) is true and is **stated on the request**:
 - Child has had a trial of behavioral therapy and has ongoing impairing and/or dangerous symptoms; **OR**
 - Child has started behavioral therapy but has extremely impairing and/or potentially dangerous symptoms; **OR**
 - Child has been referred to behavioral treatment but has extremely impairing and/or potentially dangerous symptoms that warrant treatment before therapy has had a chance to have an effect (with plan to follow up); **OR**
 - There are no known behavioral therapy resources available to this child, who has extremely impairing and/or potentially dangerous symptoms; **OR**
 - ALL of the following:
 - The child is 6 years of age; AND

- The diagnosis for the requested medication is Attention Deficit Hyperactivity Disorder (ADHD); AND
- By submitting this request, the provider attests that behavioral treatment has been prescribed in addition to the requested medication; ANDAND
- By submitting the authorization request, the prescriber attests to the following:
 - Clinical monitoring parameters recommended in prescribing information are completed at baseline, every six months, and with dosage changes; **AND**
 - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
 - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
 - The recipient has no concomitant drug therapies or disease states that limit the use of the requested medication and will not receive the requested medication with any other medication that is contraindicated or not recommended per FDA labeling;

OR

- For dDexmethylphenidate ER Capsules (generic for Focalin XR®) - there has been treatment failure or intolerable side effect with or contraindication to brand Focalin XR®; **AND-OR**
- There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; AND
- ~~For Dextroamphetamine Solution (generic for ProCentra®) - there has been treatment failure or intolerable side effect with or contraindication to brand ProCentra®; AND~~
- The child has a diagnosis approved for the medication requested (see POS Edits); **AND**
- The prescriber **states on the request** that the recipient is established on the requested medication with positive clinical outcomes; **AND**
- By submitting the authorization request, the prescriber attests to the following:
 - Clinical monitoring parameters recommended in prescribing information are completed at baseline, every six months, and with dosage changes; **AND**
 - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
 - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
 - The recipient has no concomitant drug therapies or disease states that limit the use of the requested medication and will not receive the requested medication with any other medication that is contraindicated or not recommended per FDA labeling.

Duration of Initial and Reauthorization Approval for ALL Stimulants and Related Agents (both preferred and non-preferred) for Children under 7 years of Age [except armodafinil (Nuvigil®), modafinil (Provigil®) or pitolisant (Wakix®)]: 12 months or up to the recipient's 7th birthday, whichever is less

Approval Criteria for Non-Preferred Stimulants and Related Agents [except armodafinil (Nuvigil®), modafinil (Provigil®) or pitolisant (Wakix®)] for Recipients 7 years of Age and Older:

- For ~~d~~Dexmethylphenidate ER Capsules (generic for Focalin XR®) - there has been treatment failure or intolerable side effect with or contraindication to brand Focalin XR®; **AND/OR**
- There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc; AND
- ~~For Dextroamphetamine Solution (generic for ProCentra®) — there has been treatment failure or intolerable side effect with or contraindication to brand ProCentra®; AND~~
- Previous use of a preferred product - ONE of the following is required: For all non-preferred agents, the following conditions apply:
 - ~~There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc; AND~~
 - The recipient has had *treatment failure* with at least one preferred product; **OR**
 - The recipient has had an *intolerable side effect* to at least one preferred product; **OR**
 - The recipient has *documented contraindication(s)* to the preferred products that are appropriate for the condition being treated; **OR**
 - There is *no preferred product that is appropriate* to use for the condition being treated; **OR**
 - The prescriber **states on the request** that the recipient is established on the requested medication with positive clinical outcomes; **AND**
- The recipient has a diagnosis approved for the medication requested (see POS Edits); **AND**
- By submitting the authorization request, the prescriber attests to the following:
 - Clinical monitoring parameters recommended in prescribing information are completed at baseline, every six months, and with dosage changes; **AND**
 - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
 - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
 - The recipient has no concomitant drug therapies or disease states that limit the use of the requested medication and will not receive the requested medication with any other medication that is contraindicated or not recommended per FDA labeling.

Renewal/Reauthorization Criteria for both Preferred and Non-Preferred Stimulants and Related Agents for All Ages [except armodafinil (Nuvigil®), modafinil (Provigil®) or pitolisant (Wakix®)] for Recipients 7 Years of Age and Older—

- Recipient continues to meet initial approval criteria; **AND**
- The prescriber **states on the request** that the recipient is established on the medication with evidence of a positive response to therapy.

Duration of Initial and Reauthorization Approval for all Non-Preferred Stimulants and Related Agents for All Ages [except armodafinil (Nuvigil®), modafinil (Provigil®) or pitolisant (Wakix®)] for Recipients 7 Years of Age and Older: 12 months

- ~~Initial Approval: 12 months~~

Approval Criteria for Non-Preferred Armodafinil (Nuvigil®), Modafinil (Provigil®) and Pitolisant (Wakix®)

- On the date of the request, the recipient age is:
 - 17 years of age or older for armodafinil or modafinil; **OR**
 - 18 years of age or older for pitolisant; **AND**
- ~~There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc; AND~~
- ~~Previous use of a preferred product - ONE of the following is required: The following conditions apply:~~
 - ~~There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc; AND~~
 - The recipient has had *treatment failure* with at least one preferred product; **OR**
 - The recipient has had an *intolerable side effect* to at least one preferred product; **OR**
 - The recipient has *documented contraindication(s)* to the preferred products that are appropriate for the condition being treated; **OR**
 - There is *no preferred product that is appropriate* to use for the condition being treated; **OR**
 - The prescriber **states on the request** that the recipient is established on the requested medication with positive clinical outcomes; **AND**
- The recipient has a diagnosis approved for the medication requested (see POS Edits); **AND**
- By submitting the authorization request, the prescriber attests to the following:
 - Clinical monitoring parameters recommended in prescribing information are completed at baseline, every six months, and with dosage changes; **AND**
 - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
 - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
 - The recipient has no inappropriate concomitant drug therapies or disease states.

Renewal authorization Criteria for Non-Preferred Armodafinil (Nuvigil®), Modafinil (Provigil®) and Pitolisant (Wakix®)

- Recipient continues to meet initial approval criteria; **AND**
- The prescriber **states on the request** that the recipient is established on the medication with evidence of a positive response to therapy.

Duration of ~~Authorization-Initial and Reauthorization~~ Approval for Non-Preferred Armodafinil (Nuvigil®), Modafinil (Provigil®) and Pitolisant (Wakix®): 3 months

- ~~Initial Approval: 3 months~~
- ~~Reauthorization Approval: 3 months~~

References

- Adderall (amphetamine/dextroamphetamine) [package insert]. Horsham, PA: Teva Select Brands, Division of Teva Pharmaceuticals USA, Inc; ~~December 2016~~January 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/011522s043lbl.pdf
- Adderall XR (amphetamine/dextroamphetamine) [package insert]. Lexington, MA: Shire US Inc.; July 2019. http://pi.shirecontent.com/PI/PDFs/AdderallXR_USA_ENG.PDF
- Adzenys ER (amphetamine) [package insert]. Grand Prairie, TX: Neos Therapeutics Brands, LLC; September 2017. http://www.neostxcontent.com/Labeling/AdzenysER/AdzenysER_PI.pdf
- Adzenys XR-ODT (amphetamine) [package insert]. Grand Prairie, TX: Neos Therapeutics Brands, LLC; December 2017. http://www.neostxcontent.com/Labeling/Adzenys/Adzenys_PI.pdf
- Aptensio XR (methylphenidate) [package insert]. Coventry, RI: Rhodes Pharmaceuticals L.P.; June 2019.
~~<http://www.aptensioxr.com/resources/full-prescribing-information.pdf>~~<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66&type=display>
- Concerta (methylphenidate) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2017.
https://www.janssenmd.com/pdf/concerta/concerta_pi.pdf
- Cotempla XR ODT (methylphenidate) [package insert]. Grand Prairie, TX: Neos Therapeutics Brand, LLC; June 2017. http://www.neostxcontent.com/Labeling/Cotempla/Cotempla_PI.pdf
- Daytrana (methylphenidate) [package insert]. Miami, FL: Noven Pharmaceuticals, Inc.; October 2019.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c312c31-3198-4775-91ab-294e0b4b9e7f&type=display>

Desoxyn (methamphetamine) [package insert]. Lebanon, NJ: Recordati Rare Diseases Inc; ~~March-April~~ 2019. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f03a68d5-ed00-8a2d-af68-28be909ea85f&type=display>

Dexedrine (dextroamphetamine) [package insert]. Horsham, PA: Amedra Pharmaceuticals LLC; ~~March 2017~~ ~~December 2018~~. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a37b6ef9-78b4-4b18-8797-ecb583502500&type=display>

Dyanavel XR (amphetamine) [package insert]. Monmouth Junction, NJ: Tris Pharma; February 2019. https://trispharma.com/generic/DYANAVELXR_pi.pdf

Evekeo (amphetamine) [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; ~~September 2016~~ ~~April 2019~~. <https://www.evekeo.com/pdfs/evekeo-pi.pdf>

Focalin (dexamethylphenidate) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; ~~January-November~~ 2019. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/focalin.pdf>

Focalin XR (dexamethylphenidate) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/focalinXR.pdf>

Gleason, M., Egger, H., Emslie, G., Greenhill, L., Kowatch, R., Lieberman, A., Luby, J., Owens, J., Scahill, L., Scheeringa, M., Stafford, B., Wise, B. and Zeanah, C. (2007). Psychopharmacological Treatment for Very Young Children: Contexts and Guidelines. Journal of the American Academy of Child & Adolescent Psychiatry, 46(12), pp.1532-1572.

Intuniv (guanfacine) [package insert]. Lexington, MA: Shire US Inc; ~~April~~ ~~December~~ 2019. http://pi.shirecontent.com/PI/PDFs/Intuniv_USA_ENG.pdf

Kapvay (clonidine) [package insert]. Dublin 9, Ireland: Amdipharm Limited; February 2020. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aa7700e2-ae5d-44c4-a609-76de19c705a7&type=display>

Metadate CD (methylphenidate) [package insert]. Smyrna, GA: UCB, Inc; ~~November 2016~~ ~~December 2017~~. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6aedc40-5725-4bd3-9037-033746e8599e&type=display>

Methylphenidate Chewable Tablet [package insert]. Somerset, NJ: Novel Laboratories, Inc; December 2019. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=16508cc6-13c7-4088-927a-b7206eb7c633&type=display>

Methylin (methylphenidate) Solution [package insert]. Florham Park, NJ: Shionogi Inc; February 2020. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9e3c22d9-71d9-46a7-b315-8021c94c4bec&type=display>

Mydayis (amphetamine) [package insert]. Lexington, MA: Shire US Inc; September 2019.

http://pi.shirecontent.com/PI/PDFs/Mydayis_USA_ENG.pdf

Nuvigil (armodafinil) [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; November 2018.

<https://www.nuvigil.com/globalassets/nuvigil-consumer/prescribinginformation.pdf>

ProCentra (dextroamphetamine) [package insert]. Newport, KY: Independence Pharmaceuticals, LLC; February 2017. <http://independencepharma.com/wp-content/uploads/2017/07/ProCentra-PI-MedGuide-revised-feb2017.pdf>

Provigil (modafinil) [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; November 2018.

http://www.provigil.com/PDFs/prescribing_info.pdf

Quillivant XR (methylphenidate) [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc; June 2017.

<http://labeling.pfizer.com/ShowLabeling.aspx?id=965>

QuilliChew ER (methylphenidate) [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc; March 2018.

<http://labeling.pfizer.com/ShowLabeling.aspx?id=2577>

Ritalin & Ritalin SR (methylphenidate) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; ~~November~~January 2019.

https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/ritalin_ritalin-sr.pdf

Ritalin LA (methylphenidate) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019.

https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/ritalin_la.pdf

Strattera (atomoxetine) [package insert]. Indianapolis, IN: Lilly USA, LLC; February 2020.

<https://pi.lilly.com/us/strattera-pi.pdf>

Wakix (pitolisant) [package insert]. Plymouth Meeting, PA: Harmony Biosciences, LLC; ~~November 2019~~October 2020. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8daa5562-824e-476c-9652-26ceef3d4b0e&type=display>

Vyvanse (lisdexamfetamine) [package insert]. Lexington, MA: Shire US Inc; January 2018.

http://pi.shirecontent.com/PI/PDFs/Vyvanse_USA_ENG.pdf

Zenzedi (dextroamphetamine sulfate) [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; February 2017. <http://zenzedi.com/docs/PIandMedicationGuide.pdf>

~~Gleason, M., Egger, H., Emslie, G., Greenhill, L., Kowatch, R., Lieberman, A., Luby, J., Owens, J., Seahill, L., Scheeringa, M., Stafford, B., Wise, B. and Zeanah, C. (2007). Psychopharmacological Treatment for Very Young Children: Contexts and Guidelines. Journal of the American Academy of Child & Adolescent Psychiatry, 46(12), pp.1532-1572.~~

Revision	Date
Single PDL Implemented	May 2019

Added specific wording for use of Focalin XR® and ProCentra®	November 2019
Removed POS information, added Wakix®, formatting changes, updated references	July 2020
Modified to apply new age requirement <u>for behavioral health clinical authorization,</u> <u>updated references</u>	September 2020
<u>Removed preferred wording for ProCentra®, formatting changes, updated references</u>	<u>November 2020</u>